<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acamprosate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acamprosate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Acamprosate: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11267" href="/d/html/11267.html" rel="external">see "Acamprosate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52865524"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Campral</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F129085"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        GABA Agonist/Glutamate Antagonist</li></ul></div>
<div class="block doa drugH1Div" id="F129073"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d9192803-8b96-41ab-8488-f36d16324eb4">Alcohol use disorder, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Alcohol use disorder, moderate to severe:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Alternative agent in patients who are using opioids or with acute hepatitis, liver enzymes ≥3 to 5 times normal, or liver failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29301420','lexi-content-ref-Holt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29301420','lexi-content-ref-Holt.1'])">Ref</a></span>). Initiate treatment after alcohol detoxification is complete and when the patient has achieved abstinence. Maintain treatment if the patient relapses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29301420','lexi-content-ref-SAMHSA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29301420','lexi-content-ref-SAMHSA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 666 mg 3 times daily; lower doses (eg, 666 mg 2 times daily) may be considered in patients weighing &lt;60 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20824837','lexi-content-ref-28006997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20824837','lexi-content-ref-28006997'])">Ref</a></span>). Some experts consider alternative therapy if goals are not met within 6 months of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Holt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Holt.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991626"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl 30 to 50 mL/minute: Initial dose: 333 mg 3 times daily. <b>Note</b>: The American Psychiatric Association alcohol use disorder guidelines recommend that acamprosate should not be used first-line for patients with mild to moderate renal impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29301420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29301420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≤30 mL/minute: Use is contraindicated.</p></div>
<div class="block doha drugH1Div" id="F50988909"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F129074"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F129041"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Diarrhea (17%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (≥1%), hypertension (≥1%), palpitations (≥1%), peripheral edema (≥1%), syncope (≥1%), vasodilation (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (3%), pruritus (4%), skin rash (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (≥1%), weight gain (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (≥1%), anorexia (5%), constipation (≥1%), dysgeusia (≥1%), dyspepsia (≥1%), flatulence (4%), increased appetite (≥1%), nausea (4%), vomiting (≥1%), xerostomia (3%),</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormality in thinking (≥1%), amnesia (≥1%), anxiety (8%), asthenia (7%), chills (≥1%), depression (8%), dizziness (4%), drowsiness (≥1%), headache (≥1%), insomnia (9%), pain (4%), paresthesia (3%), suicidal ideation (≤2%), suicidal tendencies (≤2%), tremor (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≥1%), back pain (≥1%), myalgia (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (≥1%), dyspnea (≥1%), flu-like symptoms (≥1%), increased cough (≥1%), pharyngitis (≥1%), rhinitis (≥1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, angina pectoris, cardiomyopathy, deep vein thrombophlebitis, heart failure, hypotension, mesenteric artery occlusion, orthostatic hypotension, phlebitis, pulmonary embolism, shock, tachycardia, varicose veins</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, alopecia, ecchymoses, eczema, exfoliative dermatitis, maculopapular rash, psoriasis, skin photosensitivity, urticaria, vesiculobullous dermatitis, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus, goiter, heavy menstrual bleeding, hyperglycemia, hyperuricemia, hyponatremia, hypothyroidism, increased lactate dehydrogenase, increased libido, increased thirst, vitamin deficiency, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distension, cholecystitis, colitis, duodenal ulcer, dysphagia, eructation, esophagitis, gastric ulcer, gastritis, gastroenteritis, gastrointestinal hemorrhage, hematemesis, hernia of abdominal cavity, melena, oral mucosa ulcer<i>,</i> pancreatitis, rectal hemorrhage, sialorrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Abnormal uterine bleeding, ejaculatory disorder, hematuria, nocturia, sexual disorder, urinary frequency, urinary incontinence, urinary tract infection, urinary urgency, vulvovaginitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, eosinophilia, hemorrhage, leukopenia, lymphadenopathy, lymphocytosis, monocytosis, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Ascites, hepatic carcinoma, hepatic cirrhosis, hepatitis, hyperbilirubinemia, increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Abscess</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams, agitation, apathy, confusion, depersonalization, encephalopathy, hallucination, hostility, hypoesthesia, malaise, manic reaction, migraine, neuralgia, neurosis, paranoid ideation, psychosis, seizure, twitching, vertigo, withdrawal syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Gout, hyperkinetic muscle activity, lower limb cramp, myopathy, neck pain, rheumatoid arthritis, torticollis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia, diplopia, ophthalmic inflammation, photophobia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine, nephrolithiasis, polyuria</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma, epistaxis, laryngismus, pneumonia</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Patnaik 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Myoclonus (Soni 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury</p></div>
<div class="block coi drugH1Div" id="F129056"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to acamprosate or any component of the formulation; severe renal impairment (CrCl ≤30 mL/minute)</p></div>
<div class="block war drugH1Div" id="F129039"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Suicidal thinking/behavior: Attempted and completed suicides have occurred in acamprosate-treated patients; use with caution in suicidal ideation. Monitor for depression and/or suicidal thinking.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Alcohol use disorder: Appropriate use: Should be used as part of a comprehensive program to treat alcohol use disorder. Treatment should be initiated as soon as possible following the period of alcohol withdrawal, when the patient has achieved abstinence. Acamprosate does not eliminate or diminish the symptoms of alcohol withdrawal.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution and reduce dose in patients with moderate renal impairment (CrCl 30 to 50 mL/minute). Use is contraindicated in patients with severe renal impairment (CrCl ≤30 mL/minute). The American Psychiatric Association alcohol use disorder guidelines recommend that acamprosate should not be used first-line for patients with mild to moderate renal impairment. (APA [Reus 2018]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfites: Traces of sulfites may be present in the formulation.</p></div>
<div class="block foc drugH1Div" id="F129049"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral, as calcium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 333 mg</p></div>
<div class="block geq drugH1Div" id="F129037"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F1793224"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Acamprosate Calcium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">333 mg (per each): $1.39 - $2.71</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865525"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral, as calcium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Campral: 333 mg</p></div>
<div class="block adm drugH1Div" id="F129053"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered without regard to meals (administered with meals during clinical trials to possibly increase compliance). Tablet should be swallowed whole; do not crush or chew.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Tablet, delayed release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. No IR formulation available.</p></div>
<div class="block use drugH1Div" id="F129052"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Alcohol use disorder, moderate to severe:</b> Maintenance of abstinence from alcohol in patients with alcohol use disorder who are abstinent at treatment initiation, as part of a comprehensive management program.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Efficacy has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning treatment. Efficacy in promoting abstinence from alcohol in polysubstance abusers has not been adequately assessed.</p></div>
<div class="block cyt drugH1Div" id="F13298632"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F129044"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block foi drugH1Div" id="F129068"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Food decreases absorption of acamprosate (not clinically significant). Management: Administer without regard to meals.</p></div>
<div class="block pri drugH1Div" id="F129058"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were observed in animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Pharmacological agents should not be used for the treatment of alcohol use disorder in pregnant women unless needed for the treatment of acute alcohol withdrawal or a coexisting disorder; agents other than acamprosate are recommended for acute alcohol withdrawal (APA [Reus 2018]).</p></div>
<div class="block brc drugH1Div" id="F20517931"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if acamprosate is present in breast milk. The manufacturer recommends that caution be exercised when administering acamprosate to breastfeeding women. Pharmacological agents should not be used for the treatment of alcohol use disorder in breastfeeding women unless needed for the treatment of acute alcohol withdrawal or a coexisting disorder; agents other than acamprosate are recommended for acute alcohol withdrawal (APA [Reus 2018]).</p></div>
<div class="block dic drugH1Div" id="F129059"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Abstinence is required for initiation of  treatment; however, treatment should be continued in the event of a relapse.</p></div>
<div class="block mop drugH1Div" id="F27855884"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function (baseline; as clinically indicated); weight (baseline; as clinically indicated); suicidal ideation.</p></div>
<div class="block pha drugH1Div" id="F129038"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Mechanism not fully defined. Structurally similar to gamma-amino butyric acid (GABA), acamprosate appears to increase the activity of the GABA-ergic system, and decreases activity of glutamate within the CNS, including a decrease in activity at N-methyl D-aspartate (NMDA) receptors; may also affect CNS calcium channels. Restores balance to GABA and glutamate activities which appear to be disrupted in alcohol use disorder. During therapeutic use, reduces alcohol intake, but does not cause a disulfiram-like reaction following alcohol ingestion. Insignificant CNS activity, outside its effect on alcohol use disorder, was observed including no anxiolytic, antiseizure, or antidepressant activity.</p></div>
<div class="block phk drugH1Div" id="F129055"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: ~1 L/kg </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: Negligible </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Not metabolized </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: ~11% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 20 to 33 hours; 1.8- and 2.6-fold longer in patients with moderate or severe renal impairment </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: 3 to 8 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51219409"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: C<sub>max</sub> in patients with moderate or severe renal impairment were 2- and 4-fold higher, respectively.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F129060"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Acamprosate mylan | Apo acamprosate | Campral</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Acamprosate biogaran | Campral ec</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Campral | Zulex</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Acamprosate biogaran | Acamprosate mylan | Aotal</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acampcon | Acamprol | Acamprost | Acmacal | Acumpros | Alcocel</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Regtect</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acamprol | Myungin acamprosate | Wi acamprosate</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Acamprosate biogaran</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Acamprosate mylan | Campral</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Acamprosate | Campral</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aotal | Campral</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Campral EC</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Aotal | Campral</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Acamprosat mylan | Campral</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Campral</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aotal</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Besobrial | Sobrial</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Acamprostate.1">
<a name="Acamprostate.1"></a>Acamprosate calcium delayed-Release tablets [prescribing information]. Mahwah, NJ: Glenmark Pharmaceuticals Inc USA; January 2022.</div>
</li>
<li>
<div class="reference">
                  Campral (acamprosate) [prescribing information]. St. Louis, MO: Forest Laboratories Inc; January 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Holt.1">
<a name="Holt.1"></a>Holt SR. Alcohol use disorder: pharmacologic management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31890411">
<a name="31890411"></a>Patnaik A, Buttar BS, Ataallah B, Kumar V. Rare anaphylactic reaction to acamprosate in a young alcoholic. <i>Cureus</i>. 2019;11(11):e6210. doi:10.7759/cureus.6210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acamprosate-drug-information/abstract-text/31890411/pubmed" id="31890411" target="_blank">31890411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29301420">
<a name="29301420"></a>Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. <i>Am J Psychiatry</i>. 2018;175(1):86-90. doi:10.1176/appi.ajp.2017.1750101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acamprosate-drug-information/abstract-text/29301420/pubmed" id="29301420" target="_blank">29301420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20824837">
<a name="20824837"></a>Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. <i>Cochrane Database Syst Rev</i>. 2010;(9):CD004332. doi:10.1002/14651858.CD004332.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acamprosate-drug-information/abstract-text/20824837/pubmed" id="20824837" target="_blank">20824837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34975141">
<a name="34975141"></a>Soni PK, Singh LK, Das S, Nandan NK. Acamprosate-induced myoclonic jerks: a rare side effect. <i>Indian J Pharmacol</i>. 2021;53(6):511-512. doi:10.4103/ijp.ijp_386_21<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acamprosate-drug-information/abstract-text/34975141/pubmed" id="34975141" target="_blank">34975141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28006997">
<a name="28006997"></a>Soyka M, Kranzler HR, Hesselbrock V, Kasper S, Mutschler J, Möller HJ; WFSBP Task Force on Treatment Guidelines for Substance Use Disorders. Guidelines for biological treatment of substance use and related disorders, part 1: alcoholism, first revision. <i>World J Biol Psychiatry</i>. 2017;18(2):86-119. doi:10.1080/15622975.2016.1246752<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acamprosate-drug-information/abstract-text/28006997/pubmed" id="28006997" target="_blank">28006997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SAMHSA.1">
<a name="SAMHSA.1"></a>Substance Abuse and Mental Health Services Administration (SAMHSA), National Institute on Alcohol Abuse and Alcoholism. <i>Medication for the Treatment of Alcohol Use Disorder: A Brief Guide</i>. Substance Abuse and Mental Health Services Administration; 2015.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9218 Version 170.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
